Hana Pharm Co., Ltd announces an Equity Buyback for KRW 2,000 million worth of its shares.
July 09, 2019 at 11:22 am IST
Share
Hana Pharm Co., Ltd (KOSE:A293480) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its shares pursuant to a trust contract with Mirae Asset Daewoo Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on January 8, 2020. As of July 8, 2019, the company had 178,551 shares in treasury within scope available for dividend and had no shares in treasury under other capacities.
HANA PHARM CO., LTD is a Korea-based company mainly engaged in the manufacturing and distribution of specialty pharmaceuticals. The companyâs main products include cardiovascular drugs involves hypertension and hyperlipidemia medicines, as well as blood circulation improvement drugs; analgesics for severe pain and anesthetics for surgery and sedation; as well as gastrointestinal drugs such as peptic ulcer treatment and antispasmodics. The Company also provides antibiotics, dermatology analgesics, antipyretics and anti-inflammatory drugs.